Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical GroupCGPHF 87 Earnings Yield (Joel Greenblatt) % is 5.45% as of Dec. 2025, which is 38% below its 10-year median of 8.80. GuruFocus rates CGPHF with a GF Score™ of 87/100. The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 73.49% on this metric.
Grand Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil.
Grand Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $211.30 Mil. Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 5.45%.
The historical rank and industry rank for Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CGPHF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.01 Med: 8.8 Max: 22.39
Current: 7.82
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Grand Pharmaceutical Group was 22.39%. The lowest was 4.01%. And the median was 8.80%.
CGPHF's Earnings Yield (Joel Greenblatt) % is ranked better than 73.49% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.25
vs CGPHF: 7.82
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Grand Pharmaceutical Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 3.23%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Grand Pharmaceutical Group (OTCPK:CGPHF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Grand Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Related Terms
Grand Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Chart
CGPHF vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % falls into.
Grand Pharmaceutical Group Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Grand Pharmaceutical Groups Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 5.45% mean?
Grand Pharmaceutical Group (CGPHF) has a Earnings Yield (Joel Greenblatt) % of 5.45% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Grand Pharmaceutical Group and its competitors. This is 38% below median its historical median of 8.80. Over the past decade, Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % has ranged from 4.01 to 22.39. According to the industry distribution chart, Grand Pharmaceutical Group ranks #267 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % too high?
Grand Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % of 5.45% is 38% below median its 10-year median of 8.80. Over the past 10 years, this metric has ranged from a low of 4.01 to a high of 22.39. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.25. Grand Pharmaceutical Group's value of 5.45% is 67.7% above this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #267 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #267 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.25. Grand Pharmaceutical Group's value of 5.45% is 67.7% above this benchmark. Historically, Grand Pharmaceutical Group's own Earnings Yield (Joel Greenblatt) % has ranged from 4.01 to 22.39 over the past decade. While the company's 10-year median is 8.80 vs. the industry median of 3.25, Grand Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.25, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % of 5.45% is 67.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Earnings Yield (Joel Greenblatt) % is 5.45%, which is 38% below median its own 10-year median of 8.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Earnings Yield (Joel Greenblatt) % of 5.45%. The current Earnings Yield (Joel Greenblatt) % is 5.45%, which is 38% below median its 10-year median of 8.80 and 67.7% above the Drug Manufacturers industry median of 3.25. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Earnings Yield (Joel Greenblatt) % is 5.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 
